Abstract
Exposure to asbestos and to other carcinogenic fibers causes mesothelioma, an aggressive tumor with poor prognosis. Tumorigenesis originates from a chronic inflammatory process driven by high mobility group box 1 (HMGB1) and the activation of the inflammatory factors, which induce the secretion of tumor necrosis factor-α (TNF-α) and other cytokines. Over time, the chronic inflammatory process induces cell survival, favoring the accumulation of DNA mutations that activate several activated pathways, promoting tumor growth. The discovery of germline heterozygous mutations of the BRCA-associated protein 1 (BAP1) gene, conferring higher susceptibility to mesothelioma, originated from studies of gene and environment interactions. Several pathways are relevant in mesothelioma, including NF2 and Hippo, receptor tyrosine kinases like EGFR and MET, intracellular kinases such as PI3K, ERK5, and others. However, HMGB1 and BAP1 represent the most frequent and key activators of oncogenic transformation and tumor progression in mesothelioma. Therefore, the pathways activated by these two proteins, both characterized by dual activity at nuclear and cytoplasmic levels, may offer the most promising perspectives for novel therapeutic approaches to antagonize a very aggressive and refractory cancer like mesothelioma.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Carbone M, Yang H. Mesothelioma: recent highlights. Annals of translational medicine. 2017;5(11):238. https://doi.org/10.21037/atm.2017.04.29.
Carbone M, Adusumilli PS, Alexander HRJ, Baas P, Bardelli F, Bononi A, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69(5):402–9. https://doi.org/10.3322/caac.21572.
Carbone M, Amelio I, Affar EB, Brugarolas J, Cannon-Albright LA, Cantley LC, et al. Consensus report of the 8 and 9th Weinman Symposia on gene x environment interaction in carcinogenesis: novel opportunities for precision medicine. Cell Death Differ. 2018;25(11):1885–904. https://doi.org/10.1038/s41418-018-0213-5.
Broaddus VC, Yang L, Scavo LM, Ernst JD, Boylan AM. Asbestos induces apoptosis of human and rabbit pleural mesothelial cells via reactive oxygen species. J Clin Invest. 1996;98(9):2050–9. https://doi.org/10.1172/JCI119010.
Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci U S A. 2006;103(27):10397–402.
Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C, et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A. 2010;107(28):12611–6. https://doi.org/10.1073/pnas.1006542107.
Carbone M, Baris YI, Bertino P, Brass B, Comertpay S, Dogan AU, et al. Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci U S A. 2011;108(33):13618–23. https://doi.org/10.1073/pnas.1105887108.
Qi F, Okimoto G, Jube S, Napolitano A, Pass HI, Laczko R, et al. Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-alpha signaling. Am J Pathol. 2013;183(5):1654–66. https://doi.org/10.1016/j.ajpath.2013.07.029.
Kadariya Y, Menges CW, Talarchek J, Cai KQ, Klein-Szanto AJ, Pietrofesa RA, et al. Inflammation-related IL-1beta/IL-1R Signaling promotes the development of Asbestos-induced malignant mesothelioma. Cancer Prev Res (Phila). 2016;9(5):406–14. https://doi.org/10.1158/1940-6207.capr-15-0347.
Thompson JK, Shukla A, Leggett AL, Munson PB, Miller JM, MacPherson MB, et al. Extracellular signal regulated kinase 5 and inflammasome in progression of mesothelioma. Oncotarget. 2018;9(1):293–305. https://doi.org/10.18632/oncotarget.22968.
Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I, et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 2012;72(13):3290–301. https://doi.org/10.1158/0008-5472.CAN-11-3481.
Yang H, Pellegrini L, Napolitano A, Giorgi C, Jube S, Preti A, et al. Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression. Cell Death Dis. 2015;6(6):e1786. https://doi.org/10.1038/cddis.2015.153.
Pellegrini L, Xue J, Larson D, Pastorino S, Jube S, Forest KH, et al. HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma. Oncotarget. 2017;8(14):22649–61. https://doi.org/10.18632/oncotarget.15152.
Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC, et al. A mouse model recapitulating molecular features of human mesothelioma. Cancer Res. 2005;65(18):8090–5. https://doi.org/10.1158/0008-5472.CAN-05-2312.
Sato T, Sekido Y. NF2/Merlin inactivation and potential therapeutic targets in mesothelioma. Int J Mol Sci. 2018;19(4) https://doi.org/10.3390/ijms19040988.
Rehrauer H, Wu L, Blum W, Pecze L, Henzi T, Serre-Beinier V, et al. How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations. Oncogene. 2018;37(20):2645–59. https://doi.org/10.1038/s41388-018-0153-z.
Heintz NH, Janssen-Heininger YM, Mossman BT. Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol. 2010;42(2):133–9. https://doi.org/10.1165/rcmb.2009-0206TR.
Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer. 2009;63(2):169–79. https://doi.org/10.1016/j.lungcan.2008.06.011.
Harvey P, Warn A, Dobbin S, Arakaki N, Daikuhara Y, Jaurand MC, et al. Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation, and morphology. Br J Cancer. 1998;77(7):1052–9. https://doi.org/10.1038/bjc.1998.176.
Ramos-Nino ME, Scapoli L, Martinelli M, Land S, Mossman BT. Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma. Cancer Res. 2003;63(13):3539–45.
Kanteti R, Riehm JJ, Dhanasingh I, Lennon FE, Mirzapoiazova T, Mambetsariev B, et al. PI3 kinase pathway and MET inhibition is efficacious in malignant pleural mesothelioma. Sci Rep. 2016;6:32992. https://doi.org/10.1038/srep32992.
Roushdy-Hammady I, Siegel J, Emri S, Testa JR, Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet. 2001;357(9254):444–5. https://doi.org/10.1016/S0140-6736(00)04013-7.
Carbone M, Emri S, Dogan AU, Steele I, Tuncer M, Pass HI, et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer. 2007;7(2):147–54. https://doi.org/10.1038/nrc2068.
Baumann F, Ambrosi JP, Carbone M. Asbestos is not just asbestos: an unrecognised health hazard. Lancet Oncol. 2013;14(7):576–8. https://doi.org/10.1016/S1470-2045(13)70257-2.
Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022–5. https://doi.org/10.1038/ng.912.
Carbone M, Ferris LK, Baumann F, Napolitano A, Lum CA, Flores EG, et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 2012;10:179. https://doi.org/10.1186/1479-5876-10-179.
Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011;48(12):856–9. https://doi.org/10.1136/jmedgenet-2011-100156.
Pilarski R, Cebulla CM, Massengill JB, Rai K, Rich T, Strong L, et al. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. Genes Chromosomes Cancer. 2014;53(2):177–82. https://doi.org/10.1002/gcc.22129.
Carbone M, Flores EG, Emi M, Johnson TA, Tsunoda T, Behner D, et al. Combined genetic and genealogic studies uncover a large BAP1 Cancer syndrome kindred tracing Back nine generations to a common ancestor from the 1700s. PLoS Genet. 2015;11(12):e1005633. https://doi.org/10.1371/journal.pgen.1005633.
Pastorino S, Yoshikawa Y, Pass HI, Emi M, Nasu M, Pagano I, et al. A subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other Germline mutations. J Clin Oncol. 2018;36:3485–94. https://doi.org/10.1200/jco.2018.79.0352.
Hassan R, Morrow B, Thomas A, Walsh T, Lee MK, Gulsuner S, et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci U S A. 2019;116(18):9008–13. https://doi.org/10.1073/pnas.1821510116.
Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, et al. Frequency of Germline mutations in Cancer susceptibility genes in malignant mesothelioma. J Clin Oncol. 2018;36(28):2863–71. https://doi.org/10.1200/jco.2018.78.5204.
Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer. 2013;13(3):153–9.
Bononi A, Yang H, Giorgi C, Patergnani S, Pellegrini L, Su M, et al. Germline BAP1 mutations induce a Warburg effect. Cell Death Differ. 2017;24(10):1694–704. https://doi.org/10.1038/cdd.2017.95.
LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015;21(11):1344–9. https://doi.org/10.1038/nm.3947.
McCambridge AJ, Napolitano A, Mansfield AS, Fennell DA, Sekido Y, Nowak AK, et al. Progress in the Management of Malignant Pleural Mesothelioma in 2017. J Thorac Oncol. 2018;13(5):606–23. https://doi.org/10.1016/j.jtho.2018.02.021.
Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H, et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol. 2015;10(4):565–76. https://doi.org/10.1097/jto.0000000000000471.
Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015;75(2):264–9. https://doi.org/10.1158/0008-5472.can-14-1008.
Lo Iacono M, Monica V, Righi L, Grosso F, Libener R, Vatrano S, et al. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. J Thorac Oncol. 2015;10(3):492–9. https://doi.org/10.1097/jto.0000000000000436.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Gaudino, G., Minaai, M., Carbone, M., Yang, H. (2021). Biomolecular Pathways in Mesothelioma: What Is New Perspective on Biomolecular Research for Mesothelioma?. In: Nakano, T., Kijima, T. (eds) Malignant Pleural Mesothelioma. Respiratory Disease Series: Diagnostic Tools and Disease Managements. Springer, Singapore. https://doi.org/10.1007/978-981-15-9158-7_4
Download citation
DOI: https://doi.org/10.1007/978-981-15-9158-7_4
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-9157-0
Online ISBN: 978-981-15-9158-7
eBook Packages: MedicineMedicine (R0)